The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide.

Article Details

Citation
Copy to clipboard

Struijs A, Mulder H

The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide.

Neth J Med. 1997 Jun;50(6):233-7.

PubMed ID
9232087 [ View in PubMed
]
Abstract

Bone mass and biochemical bone markers were prospectively studied in 33 patients with chronic obstructive pulmonary disease treated for 1 year with inhaled beclomethasone 200 micrograms/q.i.d. (group A, 8 men and 4 women), inhaled budesonide 200 micrograms/q.i.d. (group B, 6 men and 5 women), or not requiring steroids (group C, 6 men and 4 women). Both inhaled corticosteroids decreased serum concentrations of the osteoblastic markers, osteocalcin and carboxy-terminal propeptide of type I collagen (PICP). The osteoclastic marker cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) increased significantly more in patients on beclomethasone than in those on budesonide. The decrease in bone mineral density was more pronounced in patients treated with beclomethasone (1.1% in the spine 1.7% in the hip P < 0.05) compared to those treated with budesonide (0.6% in both spine and hip) or in the control group. Inhaled corticosteroids affect biochemical bone markers and bone mineral density, but there is a different effect for the two corticosteroids evaluated in the present study.

DrugBank Data that Cites this Article

Pharmaco-proteomics
DrugDrug GroupsGeneGene IDChangeInteractionChromosome
BudesonideApprovedBGLAP632
decreased		Budesonide results in decreased expression of BGLAP protein1q22
Beclomethasone dipropionateApproved InvestigationalBGLAP632
decreased		Beclomethasone results in decreased expression of BGLAP protein1q22
Beclomethasone dipropionateApproved InvestigationalBGLAP632
decreased		Beclomethasone results in decreased expression of BGLAP protein1q22